Wells Fargo & Company MN lowered its position in shares of Haemonetics Corporation (NYSE:HAE) by 1.0% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,759,457 shares of the medical instruments supplier’s stock after selling 28,665 shares during the quarter. Wells Fargo & Company MN owned 5.22% of Haemonetics worth $123,816,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Arizona State Retirement System grew its holdings in Haemonetics by 1.1% during the second quarter. Arizona State Retirement System now owns 27,397 shares of the medical instruments supplier’s stock valued at $1,082,000 after purchasing an additional 300 shares during the period. Aperio Group LLC grew its holdings in Haemonetics by 15.0% during the second quarter. Aperio Group LLC now owns 10,695 shares of the medical instruments supplier’s stock valued at $422,000 after purchasing an additional 1,393 shares during the period. Russell Investments Group Ltd. grew its holdings in Haemonetics by 12.2% during the second quarter. Russell Investments Group Ltd. now owns 23,503 shares of the medical instruments supplier’s stock valued at $928,000 after purchasing an additional 2,553 shares during the period. Stephens Inc. AR acquired a new position in Haemonetics during the second quarter valued at approximately $683,000. Finally, Schwab Charles Investment Management Inc. grew its holdings in Haemonetics by 4.5% during the second quarter. Schwab Charles Investment Management Inc. now owns 568,454 shares of the medical instruments supplier’s stock valued at $22,449,000 after purchasing an additional 24,451 shares during the period.

HAE has been the subject of a number of analyst reports. TheStreet upgraded shares of Haemonetics from a “c” rating to a “b-” rating in a report on Monday, August 7th. Zacks Investment Research upgraded shares of Haemonetics from a “hold” rating to a “buy” rating and set a $47.00 price objective for the company in a report on Wednesday, August 9th. Morgan Stanley restated an “equal weight” rating and set a $43.00 price objective (up previously from $38.00) on shares of Haemonetics in a report on Friday, October 6th. Finally, Craig Hallum restated a “hold” rating and set a $50.00 price objective (up previously from $40.00) on shares of Haemonetics in a report on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company’s stock. Haemonetics currently has a consensus rating of “Hold” and a consensus price target of $53.33.

In other news, Director Ronald G. Gelbman sold 5,440 shares of the company’s stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $56.69, for a total value of $308,393.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Dan Goldstein sold 4,691 shares of the company’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $54.93, for a total transaction of $257,676.63. Following the completion of the transaction, the chief accounting officer now owns 3,747 shares of the company’s stock, valued at approximately $205,822.71. The disclosure for this sale can be found here. Insiders sold 40,250 shares of company stock valued at $2,196,240 in the last quarter. Corporate insiders own 1.20% of the company’s stock.

Haemonetics Corporation (NYSE HAE) traded down $0.19 during trading on Monday, hitting $57.61. 896,900 shares of the stock traded hands, compared to its average volume of 354,818. The firm has a market capitalization of $3,042.86, a PE ratio of 35.34, a PEG ratio of 4.33 and a beta of 0.99. Haemonetics Corporation has a 12 month low of $36.44 and a 12 month high of $58.99. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.17 and a quick ratio of 1.51.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.48 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.41 by $0.07. The company had revenue of $225.40 million during the quarter, compared to analysts’ expectations of $219.12 million. Haemonetics had a net margin of 0.50% and a return on equity of 11.16%. The business’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.38 earnings per share. equities research analysts forecast that Haemonetics Corporation will post 1.7 EPS for the current fiscal year.

WARNING: “Wells Fargo & Company MN Sells 28,665 Shares of Haemonetics Corporation (HAE)” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.thecerbatgem.com/2017/12/04/wells-fargo-company-mn-sells-28665-shares-of-haemonetics-corporation-hae.html.

Haemonetics Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Stock Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related stocks with our FREE daily email newsletter.